



ZAI Lab announces appointment of Dr. Qi Liu as Chief Medical Officer

Shanghai, China – 25 November 2015 - Zai Lab Ltd (Zai Lab), a leading China-based biotech company focusing on developing innovative medicines for patients globally, announced today the appointment of Dr. Qi Liu as its Chief Medical Officer. Dr. Liu has extensive academic and industry drug development experience of both small molecules and biologics globally.

"We are pleased to have Dr. Liu joining the Zai team" said Samantha Du, Chief Executive Officer. "Qi is an important addition to Zai Lab. Her expertise in oncology spans from leading academic research at MD Anderson and Memorial Sloan-Kettering Cancer Centers to successful drug development with global pharma at AstraZeneca. She is deeply passionate about drug innovation and bringing solutions to patients. Zai Lab has built an extensive clinical stage pipeline, and Qi's arrival is critical as many of our programs start to enter late phase development."

Dr. Qi Liu joins Zai Lab from AstraZeneca as the clinical lead of BioVenture group and executive medical director for oncology. She played critical roles in building joint ventures for biologics development and led the JVs' global clinical development programs, regulatory strategy and submissions. During her tenure at AstraZeneca, Dr. Liu was also responsible for global development of VEGF TKI and has taken it from phase I through phase III in multiple tumor types. "I'm thrilled to join such a dynamic and globally experienced team and I shared the team's dream of building a global champion of new drug development from China," said Qi. At Zai Lab, Dr. Liu will be responsible for further building Zai Lab's portfolio, leading clinical development strategy and providing overall medical and safety oversight for Zai Lab's clinical studies.

Dr. Liu was U.S. board-certified in internal medicine, medical oncology and hematology. She was a tenure track assistant professor at MD Anderson Cancer Center prior to joining the industry. Dr. Liu received her medical degree from Fudan University Shanghai Medical College in China and PhD in molecular genetics from University of Georgia in US. She received her fellowship and clinical training at Memorial Sloan-Kettering Cancer Center, Albert Einstein College of Medicine (AECOM), and MD Anderson Cancer Center.

About Zai Lab

ZAI Lab is a leading biotech company based in China focused on discovering and developing innovative medicines for unmet medical needs globally. The company is building a strong portfolio of therapeutic programs aimed at transforming patients' lives. Zai Lab has a world class leadership team with deep experience at global pharmaceutical

and biotech organizations. The team has a strong track record of success – successfully taken five novel drug candidates into clinical trials in China, pioneered new regulatory channels, secured regulatory approvals in record times, conducted multiple IND trials in the US, and brought the first China discovered drug into Global Phase III trials. Zai Lab is committed to build a globally leading drug research and development powerhouse with a culture of excellence and teamwork and a strong focus on fostering innovation and creativity. For more information, please visit www.zailaboratory.com